IMUNON Announces Withdrawal of Form S-1 Registration Statement
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company's Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
Media
Investors
Jenna Urban
Peter Vozzo
CG Life
ICR Healthcare
212-253-8881
443-213-0505
jurban@cglife.com
peter.vozzo@icrhealthcare.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Safe Haven Defense Appoints Rudy Diaz as Chief Executive Officer
SCOTTSDALE, Ariz., June 12, 2025 /PRNewswire/ -- Safe Haven Defense US, LLC ("Safe Haven Defense"), a premier provider of branded, proprietary window security laminate systems in North America, has announced the appointment of Rodolfo "Rudy" Diaz as Chief Executive Officer, effective June 12th. Cameron Evans will step down from his role as interim CEO and will remain actively involved as a member of the Board of Directors. "I am confident that Rudy's leadership and deep experience in the security industry will help drive continued growth and success for Safe Haven Defense," said Evans. Rudy brings over three decades of leadership experience in security, risk management, and compliance. Most recently, he served as President of Gordian Risk Solutions, a firm he founded to help multinational organizations navigate complex security and operational challenges. His background includes senior leadership roles at Iron Mountain, Flex LTD, Allied Universal, SOS Security, Hewlett Packard, and GlobalFoundries. Throughout his career, Rudy has safeguarded human capital, physical assets, supply chains, and intellectual property of various enterprises across the globe. His work has supported a wide array of industries including Government, Consumer, Automotive, Technology, Healthcare, Financial, Entertainment, and Critical Infrastructure sectors. A Marquette University graduate with a BA in Criminology, Rudy is also a U.S. Marine Corps combat veteran, twice awarded the Bronze Star with "V" for valor. "I am honored to join Safe Haven Defense and look forward to advancing the Company's national expansion and strengthening partnerships across commercial and institutional markets," said Diaz. "I'm especially excited to continue the Company's mission to protect people and assets with innovative, effective, and high-impact security solutions." "We look forward to having Rudy on board to help guide Safe Haven Defense through its continued growth as the market leader in the security window laminate system market," said Steve Johnson, Founder and President of Safe Haven Defense. About Safe Haven Defense:Based in Scottsdale, AZ, Safe Haven Defense is the premier provider of branded, proprietary window security laminate solutions across North America. The company delivers cost-effective, security laminate certified by third-party accredited laboratories. Applied on-site to existing windows with minimal disruption, the film enhances protection against ballistic, forced entry, explosions, and severe weather threats. Safe Haven Defense serves a wide range of sectors including education, commercial, retail, government, and healthcare, with installations completed in over 1,000 facilities across all 50 states. For more information, please visit: View original content to download multimedia: SOURCE Safe Haven Defense US, LLC
Yahoo
13 minutes ago
- Yahoo
European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis
Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosis Florbetaben (18F) previously received orphan drug designation as a diagnostic agent for the management of amyloid light chain (AL) amyloidosis in both the EU and US The efficacy of florbetaben (18F) in diagnosing cardiac amyloidosis is being evaluated in an ongoing multi-center Phase 3 study BERLIN, June 12, 2025 /PRNewswire/ -- Life Molecular Imaging GmbH (LMI) announces today that florbetaben (18F) has been granted orphan designation by the European Commission for the diagnosis of Transthyretin (ATTR) Amyloidosis. Systemic amyloidosis is a rare group of complex diseases caused by protein misfolding and subsequent deposition in tissues, resulting in progressive organ damage. ATTR amyloidosis appears to be the most common form of amyloidosis, with incidence rates rising, likely due to prior underdiagnosis of the disease. Growing awareness of ATTR amyloidosis among cardiologists is improving recognition and diagnosis, allowing patients to access life-saving therapies. Despite the observed rise in the prevalence and incidence of cardiac ATTR amyloidosis – and its high prevalence among patients with heart failure – the overall frequency in the general population remains below the threshold for orphan drug designation (five cases per ten thousand inhabitants of newly diagnosed patients). As a result, EMA granted orphan drug designation to florbetaben (18F) as a diagnostic agent for ATTR amyloidosis. Florbetaben (18F) was initially developed and approved for the detection of neuritic amyloid plaques in the brains of patients with cognitive decline. Preliminary data suggest that florbetaben (18F) may also detect and quantify ATTR amyloid deposits in the heart and other organs using positron emission tomography (PET) imaging, thereby supporting diagnosis of the condition. The current multi-center Phase 3 trial (NCT05184088) aims to further validate florbetaben (18F)'s efficacy in the diagnosis of cardiac amyloidosis, including the ATTR subtype. "The orphan drug designation for florbetaben (18F) will support our efforts to validate this tracer for the diagnosis of both AL and ATTR cardiac amyloidosis. With the approval of several new treatment options, especially for ATTR cardiac amyloidosis, fast and reliable diagnosis of the disease becomes even more important." said Andrew Stephens, MD, PhD, Chief Medical Officer of LMI. About florbetaben (18F)Neuraceq® (florbetaben (18F)) is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. Neuraceq has been approved for routine clinical use in this indication by FDA, EMA and MHRA, and has local regulatory approval in other countries such as Canada, China, Japan, Korea, Switzerland, Taiwan. Florbetaben (18F) is currently under investigation as a targeted radiopharmaceutical for the detection of amyloid deposits in the heart and other organs of patients with cardiac and systemic amyloidosis of AL and ATTR type. Most Common Adverse ReactionsIn clinical trials including demented and non-demented subjects, the most frequently observed adverse drug reactions in 872 subjects with 1090 florbetaben (18F) administrations were injection/application site erythema (1.7%), injection site irritation (1.1%), and injection site pain (3.4%). About Life Molecular Imaging (LMI)Life Molecular Imaging GmbH, together with its affiliates in the UK and US (LMI) is a radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit LMI, a member of the Life Healthcare group of companies, is being acquired by Lantheus Holdings, Inc. For more information about the pending acquisition, please visit For media queriesBrittany Hahn | Marketing Communications Manager | Life Molecular ImagingTel: +1.484.735.2840 | For scientific information Iris Hardewig | Clinical Development| Life Molecular ImagingTel. +49 151 14569896| View original content to download multimedia: SOURCE Life Molecular Imaging Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
BIC: Disclosure of total number of voting rights and number of shares forming the capital as of May 31, 2025
Disclosure of total number of voting rights andnumber of shares forming the capitalas of May 31, 2025 Clichy, France – June 12, 2025 Article L 233-8-II of the French 'Code de Commerce' and Article 223-16 of the General Regulations of the French 'Autorité des Marchés Financiers'. As of May 31, 2025, the total number of issued shares of Société BIC is 41,621,162 shares, representing: - 58,877,719 voting rights, - 58,480,587 voting rights excluding shares without voting rights Contacts Brice ParisVP Investor Relations +33 6 42 87 54 Investor Bethridge ToovellVP Global Communications+1 917 821 Isabelle de Segonzac Image 7, Press Relations contact+33 6 89 87 61 39isegonzac@ Agenda All dates to be confirmed First Half 2025 Results July 30, 2025 Third Quarter 2025 Net Sales October 28, 2025 About BIC A global leader in stationery, lighters, and shavers, BIC brings simplicity and joy to everyday life. For 80 years, BIC's commitment to delivering high-quality, affordable, and trusted products has established BIC as a symbol of reliability and innovation. With a presence in over 160 countries, and over 13,000 team members worldwide, BIC's portfolio includes iconic brands and products such as BIC® 4-Color™, BodyMark®, Cello®, Cristal®, Inkbox®, BIC Kids®, Lucky™, Rocketbook®, Tattly®, Tipp-Ex®, Wite-Out®, Djeep®, EZ Load™, EZ Reach®, BIC® Flex™, Soleil®, Tangle Teezer® and more. Listed on Euronext Paris and included in the SBF120 and CAC Mid 60 indexes, BIC is also recognized for its steadfast commitments to sustainability and education. For more, visit and to see BIC's full range of products visit Follow BIC on LinkedIn, Instagram, YouTube and TikTok. Attachment BIC_Voting rights_MAY25Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
